0263-6352 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins Abstracts e5 Methods: This prospective study included 315 pregnant women between weeks 10 th and 13 th of pregnancy that were referred from the Prenatal Diagnosis Unit of Hospital Clínico San Carlos, Madrid. Exclusion criteria: multiple gestation, chronic hypertension, cardiovascular pathology, creatinine >1.3mg/dL, hypo- thyroidism, autoimmune diseases, Diabetes Mellitus, previous gestational dia- betes, treatment with methotrexate or antiepileptic drugs, previous PIH or PE and maternal age over 40. We measured in every trimester: total cholesterol, HDL- cholesterol, triglycerides, uric acid, creatinine, cystatin-C, CRP, with PAPP-A and free-ßHCG being measured only in the first trimester specimen. Samples were obtained on the obstetric visit day. PIH was defined as BP ≥140 and/or ≥90mmHg (two times with a six hour time interval), after the 20th week of preg- nancy. PE was considered as PIH and proteinuria. (≥ 300mg/24hours or ≥30mg/ dL). For the statistical analysis c2 (or Fisher´s), t-student, and non parametric median tests were used. ROC and multiple logistic regression analysis were used. Results: When comparing PIH status (6.1%) vs control pregnant women, the study shows significant statistical differences in the following way: in the first trimester (weeks 10 th -13 th ) in BMI (p = 0.01) and uric acid (p = 0.02), in the second trimester (weeks 20 th -22 th ) in HDL-cholesterol (p = 0.02) and in the third trimester (weeks 31 th -33 th ) in total cholesterol (p = 0.04) and uric acid (p<0.001). Moreover results showed an increase in the risk of PIH for Uric acid >3.15mg/dL in the 1 st trimester (p = 0.01) and for creatinine >0.69mg/ dL and HDL-cholesterol <66.50mg/dL in the 2 nd trimester (p = 0.006 and p = 0.007). In addition, when we considered an increase in the rate of change of uric acid and cystatin-C between 1 st and 2 nd trimesters we found that the risk of PIH increases (RR = 2.76 and RR = 4.10 respectively). Conclusion: This study suggests that the renal function biomarkers seem to play a potential role in the early prediction of Pregnancy-induced hypertension. 1B.03 METABOLIC PROFILE, PATTERNS OF METABOLIC CONTROL BY TREATMENT AND RELATIONSHIPS WITH BLOOD PRESSURE VALUES IN PATIENTS FROM CENTRAL AND EASTERN EUROPEAN COUNTRIES: THE BP-CARE METABOLIC STUDY G. Brambilla 1 , G. Seravalle 2 , R Cifkova 3 , S. Laurent 4 , K. Narkiewicz 5 , J. Redon 6 , C. Farsang 7 , M. Bombelli 1 , C. Giannattasio 1 , G. Mancia1, G. Grassi 1 . 1 Clinica Medica, Ospedale San Gerardo-Univeristà Milano-Bicocca, Monza-Italy, 2 Istituto Auxologico Italiano, Milan-Italy, 3 Institute of Clinical and Experimental Medicine, Prague-Czech Republic, 4 Pharmacology Department, Hopital Europeen Georges Pompidou, Paris-France, 5 Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk- Poland, 6 Internal Medicine, Hospital Clinico, University of Valencia, Valencia- Spain, 7 Cardiometabolic Department, St Imre Teaching Hospital, Budapest-Hungary Introduction: The BP-CARE study has recently provided information on the cardiovascular (CV) risk profile and blood pressure (BP) control in treated hypertensive patients in Albania, Belarus, Bosnia, Czech Republic, Latvia, Romania, Serbia, Slovakia, Ukraine (Eur Heart J. 2011,). Few and limited to selected geographic areas are the data collected on the metabolic profile, patterns of metabolic control and relationships with BP values in patients of Central and Eastern European countries. Methods: In 3798 subjects (males 50.1%) living in the above mentioned countries we examined clinic BP, total cholesterol, HDL-cholesterol, plasma triglycerides, fasting blood glucose and percent of patients treated with oral antidiabetic agents/insulin and/or statins/fibrates. We also examined the rela- tionships between the patterns of the metabolic abnormalities and the 1) sever- ity of the hypertensive state, 2) CV risk profile and 3) level of BP control (quartiles of BP). Finally the main features of the metabolic control induced by treatment were also evaluated. Results: Recruited subjects aged 59.9 ± 11.0 years (mean ± SD), and displayed values of total cholesterol amounting to 208.9 ± 45.9 mg/dl, HDL to 48.5 ± 14.0 mg/dl, LDL to 146.6 ± 44.5 mg/dl, triglycerides to 169.4 ± 64.0 mg/dl and blood glucose to 108.6 ± 37.0 mg/dl. In 86.6% of the population sample a dyslipidaemic state was detected (ATP III criteria and/or specific drugs) and a diabetic or a pre-diabetic state (ADA criteria) was found in 29.8% and 23.1% of the population, respectively. The prevalence of dyslipidaemia and diabetes ORAL SESSION ORAL SESSION 1B EPIDEMIOLOGY 1B.01 IMPACT OF NADIR CD4 CELL COUNT AND ANTIRETROVIRAL THERAPY ON HYPERTENSION IN A LONGITUDINAL STUDY OF HIV-INFECTED INDIVIDUALS I. W. Manner 1 , M. Baekken 2 , O. Oektedalen 3 , I. Os 1 . 1 Faculty of Medicine, University of OSLO, OSLO-Norway, 2 Dept of Nephrology, OSLO University Hospital, OSLO-Norway, 3 Dept of Infectious Diseases, OSLO University Hospital, OSLO-Norway Objective: Little is known about the development of hypertension over time in HIV-infected patients. In a longitudinal study of an HIV-infected cohort, the prevalence and new development of hypertension were assessed. Design and Method: In a cohort of 434 HIV-infected individuals, blood pres- sure (BP) was measured in duplicate at 3 different visits at baseline and after 3.4 ± 0.8 years. Hypertension was defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg or use of antihypertensive medication. Results: In this cohort (71.4% Caucasians and 72.1% males, mean age 43.1 ± 10.5 years) the duration of known HIV infection at baseline was 7.4 ± 5.9 years with CD4 cell count 0.38 (IQR 0.25 –0.57) 10 9 cells/l, nadir CD4 cell count 0.15 (IQR 0.06 – 0.21) 10 9 cells/l, duration of antiretroviral therapy (ART) 2.5 (IQR 0.1 – 5.8) years, whereas 100 patients (23%) were ART-naïve. BP at baseline was 131.1 ± 18.1/81.6 ± 10.9 mmHg, and HT was present in 34.8%. The prevalence of HT was unchanged during follow-up, 34.8%. In the 127 hypertensive persons without AHT at baseline, 29 (22.8%) were no longer hypertensive, while 29 (10.2%) of 283 normotensive developed hypertension. Use of antihypertensive treatment (AHT) increased from 15.9 to 33.1% (p < 0.0001) during this time period. HT at follow-up was associated with older age, male gender, Caucasian ethnicity, higher BMI and cholesterol, nadir CD4 cell count <0.05 10 9 cells/l, longer duration of HIV infection as well as of ART, reduced GFR, and increased urinary albumin excretion (ACR) in univariate analyses. In multivariate analyses, duration of ART (log transformed, OR 1.63 (95% CI 1.18 - 2.24) and nadir CD4 cell count < 0.05 10 9 cells/l (OR 2.03 (95% CI 1.13 – 3.64) as well as age, cholesterol, BMI, and ACR were independent predictors of HT at follow-up after adjustment. Conclusions: Hypertension in this cohort was influenced by low nadir CD4 cell count and increased duration of ART in addition to traditional risk factors. Thus, preserved immunocompetence may be of importance for future blood pressure development. The high number of patients that became normotensive during the follow-up suggest that more extensive use of 24-h ambulatory BP readings should be used to ensure correct diagnosis. The doubling of patients receiving AHT during the short follow-up may indicate an increased aware- ness of hypertension and the importance of AHT in this population. 1B.02 BIOCHEMICAL PREDICTORS OF PREGNANCY-INDUCED HYPERTENSION N. Martell-Claros 1 , M. ABAD-Cardiel 1 , F. Blanco-Kelly 2 , M. A. Herráiz 3 , M. E. Fuentes 4 , M. J. Torrejon 2 , A. Fernandez-Cruz 1 . 1 Hypertension Unit. H. Clinico SAN Carlos. Madrid, Marid-Spain, 2 Clinical Chemistry Department. H. Clinico SAN Carlos., Madrid-Spain, 3 Gynaecology and Obstetrics Department. H. Clinico SAN Carlos., Madrid-Spain, 4 Epidemiology and Preventive Medicine Department. H. Clinico SAN Carlos., Madrid-Spain Pregnancy-induced hypertension (PIH) and Preeclampsia (PE) are multi-system and pregnancy- specific disorders. They contribute substantially to perinatal morbidity and mortality of both mother and fetus. In recent years many bio- chemical maternal markers have been evaluated, but until now none of them have shown clear reliability for use in practice. Aim: To evaluate if any of the biochemical markers used in the monitoring of pregnancy can be used as early predictors of the development of pregnancy- induced hypertension. S A T U R D A Y O R A L S